Drilldown: Medicines

None (2) · Irbesartan (1) · Olmesartan (medoxomil) (1) · Telmisartan (1)

Ajovy (1) · Avapro (1) · Benicar (1) · Emgality (1) · Micardis (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (3) · [[:Category:Antihypertensives|Antihypertensive]] (3)

None (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) · '"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-0000056B-QINU`"' (1) · '"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) · '"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1)

150 mg PO once daily; titrate to 300 mg if needed (1) · 20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 40 mg PO once daily; titrate to 80 mg (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 20, 40, 80 mg tablets (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 5, 20, 40 mg tablets (1) · 75, 150, 300 mg tablets (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/d (1) · 40 mg/d (1) · 675 mg/quarter (1) · 80 mg/d (1)

Oral (3) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 hours (3) · Monthly dosing (1) · Monthly or quarterly dosing (1)

11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) · ~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) · ~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) · ~27 days (1) · ~31 days (1)

42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) · 60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1) · ~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1)

'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) · Limited data; avoid (2)

Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (3)